Large-scale human myeloma cell line small molecule compound screen dataset

Abstract

Multiple myeloma, a hematopoietic malignancy of terminally differentiated B cells, is the second most common hematological malignancy after leukemia. While patients have benefited from numerous advances in treatment in recent years resulting in significant increases to average survival time following diagnosis, myeloma remains incurable and relapse is common. To help identify novel therapeutic agents with efficacy against the disease and to search for biomarkers associated with differential response to treatment, a large-scale pharmacological screen was performed with 1,912 small molecule compounds tested at 11 doses for 47 human myeloma cell lines (HMCL). Raw and processed versions of the drug screen dataset are provided, as well as supportive information including drug and cell line metadata and high-level characterization of the most salient features of each. The dataset is publicly available at Zenodo and the workflow code used for data processing and generation of supporting figures and tables are available on GitHub.

Fig. 1

Experimental workflow. High-level overview of data generation and processing pipeline.

Fig. 2

Plate map. Reference plate image depicting the locations of control wells and arrangement of treated wells for different drugs and concentrations. A raw L363 plate (T5612674) is used as an example.

Fig. 3

High-level view of differences in drug efficacy and cellular response to treatment. (a) For each cell line and dose increment, mean viability across all 1,912 compounds was computed and the resulting dose-response curves were plotted. (b) For each drug, median AC-50 values were computed and a histogram of the resulting averages was plotted.